Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them.

International journal of molecular sciences - 29 Jul 2022

Kim Dongha, Nam Hye Jin

Abstract excerpt

PARP inhibitors are the first clinically approved drugs that were developed based on synthetic lethality. PARP inhibitors have shown promising outcomes since their clinical applications and have recently been approved as maintenance treatment for cancer patients with BRCA mutations. PARP inhibitors also exhibit positive results even in patients without homologous recombination (HR) deficiency. Therapeutic effects...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Ovarian Neoplasms

Share to PARP inhibition in cancer therapy

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Synthetic Lethal Mutations

Source

Open in PubMed Open full text

Identifiers

PMID: 35955544
DOI: 10.3390/ijms23158412
PMCID: PMC9369301

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them.PMID 35955544Read ↗

Mechanism of PARP inhibitor resistance and potential overcoming strategiesSemantic proximity Read ↗

PARP Inhibitors Resistance: Mechanisms and PerspectivesSemantic proximity Read ↗

Clinical approaches to overcome PARP inhibitor resistanceSemantic proximity Read ↗

Combination Treatment Strategies to Overcome PARP Inhibitor ResistanceSemantic proximity Read ↗

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP InhibitorsSemantic proximity Read ↗

Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancerSemantic proximity Read ↗

PARP inhibitor resistance: the underlying mechanisms and clinical implicationsSemantic proximity Read ↗

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistanceSemantic proximity Read ↗

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic ApproachesSemantic proximity Read ↗

Molecular mechanism of PARP inhibitor resistanceSemantic proximity Read ↗

Facing inevitable PARPis resistance: Mechanisms and therapeutic strategies for breast cancer treatmentSemantic proximity Read ↗

Advances and perspectives of PARP inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.